Between June 1988 and January 1980, 67 patients with pathologic stage III non-small cell lung cancer were randomized to receive either preoperative mitomycin, vinblastine, and cisplatin (MVP) chemotherapy (cisplatin 120 mg/mi2, and mitomycin, 8 mg/mi2 day 1+29, and vinblastine, 4 .5 mg/m2 on day 1, 15, 22 , and 29 and 2.0 mg/m2 day 8) , or preoperative radiotherapy (44 Gy in 22 fractions to the primary tumor and mediastinum). The purpose of this study was to identify a treatment approach that showed sufficient effectiveness and acceptable toxicity to warrant testing by prospective randomized trial against "standard" nonsurgical treatment. All patients had surgical staging of the mediastinum and had either unresectable N2 disease or T4 disease with proximal extension of disease along the pulmonary artery. Response to preoperative therapy was evaluated 8 weeks after beginning treatment and patients with complete or partial radiographic response were to undergo surgical exploration and resection if possible. Fifty-seven patients were eligible and evaluable for response. Of the 67 total patients, 3 were unavailable for follow-up, 4 were ineligible, 1 24 underwent surgical exploration and 20 underwent resection, of which 18 were complete. The mediastinum was free of tumor in seven patients but only two pathologic complete responses were seen (one each to XRT and MVP). In addition, ten nonresponders underwent surgery; seven underwent resection. Median survival for the entire group is 12 months, with a 27% actuarial survival at 4 years. Two patients died of treatment toxicity during preoperative therapy. Overall toxicity included 2 preoperative toxic deaths and 6 postoperative deaths in 34 patients who underwent surgical exploration (3 each with XRT and MVP) due to adult respiratory distress syndrome (3), myocardial infarction (1) , pulmonary edema (1) , and esophageal fistula (1) , for an overall death rate 8 of 57 (14%) and a perioperative death rate in surgically explored patients of 6/34 (18%). These preoperative regimens, in the population studied herein, were of modest efficacy and substantial toxicity. While these data do not exclude possible gain in long-term survival for these preoperative treatments compared with the best nonsurgical therapy, until such benefits are documented in prospective trials, their use should be considered investigational.
urvival of patients with non-small cell lung cancer (NSCLC) metastatic to mediastinal lymph nodes or extending directly into the mediastinum is poor. Even when these patients have technically resectable, conditions, surgical treatment leads to long-term disease-free survival in only about 10% of patients except for a more favorable subgroup group of patients who preoperatively appear to have NI disease and are found only on inspection of the resected specimen to have microscopic intranodal N2 disease. [1] [2] [3] In most North American institutions, these patients have traditionally been treated with radiation therapy with the expectation of palliation or delay of disease progression for the majority of patients and cure for a small minority. Three-year disease-free survival rates for all patients are about 5 to 8%, while for selected patients with high performance status, they may be as high as 10 to 15%.4 With doses of 60 to 65 Gy in daily fractions of 2.0 Gy, local control is only about 20%, although freedom from clinical progression in the chest appears higher because of the rapid death of many patients from systemic disease progression. Several recent phase 3 trials have shown modest but significant improvements in median and longterm survival with the use of either sequential6-9 or concurrentl chemotherapy in addition to radiation therapy. Effective strategies have used chemotherapy both as a systemic agent, using cyclic administration of standard doses of active drugs, and the daily use of low dose cisplatin as a radiation sensitizer. These data would validate strategies aimed at improving both local and systemic disease control in improving outcome for patients with "unresectable" N2 or T4 NSCLC.
The failure of single-treatment modalities to achieve local or systemic control in most of these patients has led to attempts to combine two or more modalities in their treatment. The North American Lung Cancer Study Group (LCSG) has investigated the possibility of including surgical resection in these patients following a preoperative cytoreductive treatment. Two previous trials, LCSG 831 and LCSG 852, using concurrent radiation and chemotherapy as preoperative regimens, indicated that it was possible to perform resections in about 30 Initial staging evaluation included a posteroanterior and lateral chest radiograph, CT scan of the chest and upper abdomen, including the liver and adrenals, CT scan of the brain, and bone scan. All patients underwent mediastinal surgical exploration by mediastinoscopy, mediastinotomy, thoracotomy, or a combination of these procedures to allow a judgment to be made regarding resectability and to obtain pathologic confirmation of radiographically suspected mediastinal adenopathy or direct extension.
Surgeons were to specify the reason(s) for unresectability in each patient.
Patients were eligible if they had either N2 disease which, by virtue of its extent could not be resected without leaving residual tumor, or T4 disease limited to proximal extension of tumor along the pulmonary artery. Patients who were considered eligible on the basis of their N2 involvement were required to have evidence at mediastinal surgical exploration of positive nodes at levels 2R, 2L, 4R, lOR, lOL, five or six which were considered unresectable. Positive subearinal nodes (level 7) at mediastinoscopy were considered de facto unresectable. Patients with more extensive T4 disease not limited to proximal pulmonary artery involvement, as well as those with N3 disease, were excluded.
Patients were required to have a Karnofsky performance status of 70 or above and to have normal bone marrow, hepatic, and renal function. There was no formal cutoff for weight loss. Patients with recent myocardial infarction, uncontrolled congestive heart failure or angina pectoris, or other serious active medical problems, including second malignant neoplasms other than skin cancer, were excluded. All patients had baseline electrocardiograms and assessment of pulmonary function with measurement of FEVI, FVC, and arterial blood gas determinations. Radiation Therapy
Preoperative radiation therapy was directed at a volume that encompassed the primary tumor mass, ipsilateral hilar, bilateral tracheobronchial, subcarinal, and superior mediastinal nodes to the level of the lung apex. Neither supraclavicular nor contralateral hilar nodes were routinely included in the treated volume. All patients underwent simulation prior to the start of treatment and simulator radiographs, treatment beam radiographs, and isodose plans in the central plane as well as calculations of the spinal cord dose in planes 2 cm above the inferior field border and 2 cm below the superior field border were submitted for review by the Quality Assurance Reference Center.
The planned target volume dose was 44 Gy in 22 daily fractions of 2.0 Gy given over a period of 5 weeks. Treatment was to be given with opposed anterior and posterior fields for most treatment, with oblique fields used for that portion of treatment needed to limit the maximum spinal cord dose to 45 Gy. Posterior spinal cord blocks were forbidden. Dose variation in the treatment volume was to be kept within ±5%.
Preoperative Chemotherapy
Preoperative chemotherapy was given with the MVP regimen as described by Martini et assessed with a repeat of the on-study evaluation. Computed tomographic scans of the upper abdomen and brain and bone scans were repeated only on clinical suspicion of metastases. Bronchoscopy was repeated only if needed to assess resectability. Patients achieving complete or partial radiographic response were to undergo thoracotomy and attempted resection. Nonresponders and patients with stable disease were taken off study and treated or followed at their preference and that of their treating physicians.
Statistical Considerations
The purpose of these phase 2 trials was to evaluate the efficacy and toxicity of these preoperative treatment programs. The goal was to identify a treatment approach with sufficient effectiveness to warrant testing by prospective randomized trial against "best" nonsurgical treatment. Patients were randomized only to ensure anatomic and physiologic similarity of the populations undergoing simultaneous but independent treatment programs. These two simultaneous trials were not of sufficient size to allow comparison of results. The original study design called for 50 patients to be entered on each arm. With the inactivation of the LCSG in 1989, accrual was terminated and only 67 patients were entered to the entire trial. The individual studies were designed to estimate resectability rates with 95% confidence limits for the observed resection rates of + 20%. With the reduced sample size, these limits are widened. Follow-up of these patients for events occurring after the closure of the LCSG data management office has required manual contact with individual investigators.
The specific end points for these studies were radiologic response, resection rates, and histologic complete response rates for the two treatment regimens, as well as treatment-related toxicity. Patients were followed up for survival and patterns of relapse but these were not primary end points of the study. After completion of surgical resection or confirmation of nonresectability, additional therapy was not mandated by the study but could be given.
Comparisons between groups and life table calculations were performed using a software package (Kwikstat, version 3.0, TexaSoft, Cedar Hill, Texas).
RESULTS

Patient and Tumor Characteristics
These studies were opened in April 1988 and closed to patient accrual in January 1990. Sixty-seven patients were entered, of whom 4 were ineligible, 1 cancelled, 2 refused any treatment, and 3 were unavailable for follow-up. This report is based on 57 patients who were properly entered and eligible for analysis of response. (XRT) . Ten patients showed objective disease progression during preoperative therapy, five in the lung or pleura, three in supraclavicular nodes (one of these also in lung), and three in distant visceral sites (bone, neck, brain). No difference was seen in response rates for squamous and nonsquamous histologic features. 
Surgical Results
Thirty-four patients were explored surgically after their induction treatment (Table 5 ). The rate of exploration was a function of response, with 1 of 1 with CR, 23 of 28 with PR, 9 of 16 with stable disease, and 1 of 10 with progressive disease in patients undergoing exploration. Resection was accomplished in 27 of the 34 surgically explored patients for a rate of 79% or 47% of the evaluable ones. Four of these resections are known to have been incomplete for a complete resection rate of 22 of 57 or 39%. Viable appearing tumor was present in all but two of the resection specimens (one each with preoperative MVP and XRT) for an overall histologic complete response rate of 2/57 or 3.5% (Table 6 ).
Treatment Toxicity
Acute toxicity was largely as expected, with moderate esophagitis and little myelosuppression in patients receiving XRT and significant myelosuppression in patients receiving MVP. Drug doses required attenuation in 12 of 24 patients during their second dose of cisplatin and mitomycin (2 of 26 did not receive a second cycle, one because of death and one refusal). One patient had to discontinue chemotherapy because of severe ototoxicity after one dose of cisplatin.
Two patients died of toxic reactions during induction treatment and six died in the perioperative and postoperative period for an overall toxic death rate of 8/57 (14%) (Tables 4-7) . The induction deaths were due to sepsis in a patient receiving MVP and development of a bronchopleural fistula in a patient receiving XRT. Three perioperative or postoperative deaths were seen in each treatment arm, with deaths due to adult respiratory distress syndrome (ARDS), myocardial infarction (MI), and pulmonary edema in the MVP group, and ARDS, pulmonary embolism (two patients each), MI (one patient who also had ARDS and pulmonary embolism), and development of a bronchoesophageal fistula in the XRT group. The patient in the chemotherapy group who died of ARDS had mediastinal nodal disease that was resected, was given postoperative radiation therapy to the mediastinum for residual disease, and died of acute radiation pneumonitis. Such postoperative radiation was permitted but not required on the study.
Recurrence and Survival
The overall median survival for the 57 patients on this study was 12 months. We do not view median survival as a particularly useful indicator of the value of a preoperative regimen, the aim of which was to increase the fraction of long-term survivors. These values, however, may reflect Partial response 16 12 Stable disease 5 11 Progressive disease 4 6 Early death 1 1 6 deaths from perioperative or postoperative toxicity, 4 alive with no evidence of disease) or 65%. It has been difficult to obtain such data on patients being followed up in local community institutions now that the LCSG Operations Office is nonexistent. The submitted data may represent a biased subset of all data. With these reservations, it is notable that both local and distant failure have remained common in these patients as first relapse sites (Table 7) . Eleven patients had failures in the ipsilateral hemithorax, four of these with pleural involvement. Three had failures in supraclavicular nodes. There were four initially exclusive brain metastases, and 15 patients failing in non-central nervous system (CNS) distant sites. One patient developed a second primary lung cancer. (Several patients had multiple sites of first failure, so numbers do not sum to 32.) In the 27 patients with resections, sites of first recurrence were documented in 18, of which 3 were local, 2 brain, 8 distant non-CNS, 1 second primary, and 4 alive without relapse. While the numbers were small, there were no obvious differences in patterns of failure between the XRT and MVP groups. There did, however, appear to be a trend to fewer patients with a local component of failure in the group undergoing resection as compared with patients not undergoing resection (3/27 vs 7/30), but this is hardly surprising. Relapse in the CNS in patients otherwise apparently free of disease occurred in only 2 of 27 (7%) patients.
DISCUSSION
Our main goals in this study were to determine the resection rates and histologic complete response rates for these two preoperative regimens. Despite the premature closure of the study, we accrued 67 of the planned 100 patients and can make tentative conclusions based on the 57 evaluable cases. Both the preoperative XRT and MVP chemotherapy regimens as used herein produced objective radiographic responses in about half of the patients treated, 13 of 24 (54%) for MVP and 12 of 25 (48%) for XRT. Surgical exploration was carried out in 34 patients, 27 of whom underwent resection (27/57 or 48% of all evaluable patients), 14 from the MVP and 12 from the XRT groups. In 4 of these patients, tumor was known to have been left, for a maximum complete resection rate of 23 of 57 (40%). However, only two patients had a histologic complete response with no viable tumor found in the resected specimen. The histologic complete response rate was thus only 2 of 57 (4%). Both the overall resectability rate and histologic complete response rates of these two single modality arms are toward the low end of those reported in the prior LCSG trials and by other groups. Since these single modality regimens were as toxic as the combined radiochemotherapy regimens reported, it appears that such combined radiochemotherapy may be preferable as a preoperative regimen, as suggested by Fleck et al.24 It is premature and was not the purpose of these pilot studies to speculate on any possible long-term survival benefits for patients receiving either of these regimens. The overall median survival of 12 months is not dissimilar to that reported for ostensibly similar groups of patients treated with radiation alone, radiation plus chemotherapy, or with the preoperative regimens that we have explored in the LCSG 831 and 853 trials. This may point out the inadequacy of using median survival as an indicator of the efficacy of a strategy whose goal and possible benefit, if any, would be to increase the proportion of long-term survivors. A treatment regimen might succeed at this but have sufficient early morbidity to produce a reduction rather than an increase in median survival. Whether such a treatment strategy would be desirable would depend 
